natgillin/translations-raw huggingface dataset:
Patients should inform physicians and dentists that they are taking clopidogrel before any surgery is scheduled and before any new medicinal product is taken. 
Bolesnici moraju obavijestiti liječnika i stomatologa o uzimanju klopidogrela prije planiranja bilo kakvog kirurškog zahvata i prije uzimanja bilo kojeg novog lijeka.
For the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow. 
Za liječenje tog stanja liječnik Vam može ugraditi stent (potpornicu) u začepljenu ili suženu arteriju da bi ponovno uspostavio učinkovit protok krvi.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia Pharmachemie B.V., Swensweg 5, 2031 GA Haarlem, The Netherlands 
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija Pharmachemie B.V., Swensweg 5, 2031 GA Haarlem, Nizozemska
The elimination half-life of the main circulating (inactive) metabolite was 8 hours after single and repeated administration. 
Poluvijek eliminacije glavnog cirkulirajućeg (neaktivnog) metabolita iznosio je 8 sati nakon jednokratne i ponovljene primjene.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu. 
Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove: http://www.ema.europa.eu/
The mean bleeding time prolongation was also similar in the two groups. 
Srednje produljenje vremena krvarenja također je bilo slično u obje skupine.
• You should tell your doctor if a surgery (including dental) is planned 
Obavijestite svog liječnika ako planirate kirurški zahvat (uključujući stomatološke zahvate).
• if you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days 
Ako ste imali krvni ugrušak u arteriji u mozgu (ishemijski moždani udar) koji se pojavio unutar posljednjih sedam dana.
PHARMACEUTICAL FORM Film-coated tablet. 
Filmom obložena tableta.
If you take more Clopidogrel Teva Generics B.V. than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding. 
Ako uzmete više tableta Klopidogrel Teva Generics B.V. nego što ste trebali Odmah se morate javiti liječniku ili u najbliži odjel hitne medicinske pomoći zbog povećanog rizika od krvarenja.
Pharmacovigilance system 
Farmakovigilancijski sustav
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs. 
Međutim, zbog nepostojanja studija u kojima se prati interakcija s drugim lijekovima iz skupine NSAIL za sada nije jasno odnosi li se povećani rizik od gastrointestinalnog krvarenja na sve nesteroidne protuupalne lijekove.
Since higher doses of ASA were associated with higher bleeding risk it is recommended that the dose of ASA should not be higher than 100 mg. 
Budući da se više doze acetilsalicilne kiseline povezuju s visokim rizikom od krvarenja, preporučuje se da doza ASK ne bude veća od 100 mg.
However, clopidogrel and ASA have been administered together for up to one year (see section 5.1). 
Međutim, klopidogrel i ASK istodobno su primjenjivani u trajanju do jedne godine (vidjeti dio 5.1.).
Cytochrome P450 2C19 (CYP2C19) 
Citokrom P450 2C19 (CYP2C19)
If a patient is to undergo elective surgery and antiplatelet effect is temporarily not desirable, clopidogrel should be discontinued 7 days prior to surgery. 
Ako se bolesnik planira podvrgnuti elektivnom kirurškom zahvatu, pa antitrombocitni učinak trenutno nije poželjan, primjenu klopidogrela treba prekinuti 7 dana prije zahvata.
In patients suffering from acute coronary syndrome: 
Bolesnici s akutnim koronarnim sindromom:
Their frequency is defined using the following conventions: common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare 
Njihova je učestalost definirana na sljedeći način: česte (≥1/100, <1/10); manje česte (≥1/1000, <1/100); rijetke (≥1/10 000, <1/1000); vrlo rijetke (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
In addition, a subgroup analysis by age suggested that the benefit of clopidogrel in patients over 75 years was less than that observed in patients ≤75 years. 
Dodatno, analiza podskupina prema dobi ukazuje da je korist od liječenja klopidogrelom manja u bolesnika iznad 75 godina nego u onih ≤75 godina.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu/. 
Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove http://www.ema.europa.eu
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder 
Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje u gotovog lijeka u promet:
Taking Clopidogrel Teva Generics B.V. with food and drink Clopidogrel Teva Generics B.V. may be taken with or without food. 
Klopidogrel Teva Generics B.V. s hranom i pićem Klopidogrel Teva Generics B.V može se uzimati s obrokom ili bez obroka.
For a full list of excipients, see section 6.1. 
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
Ask your doctor or pharmacist for advice before taking any medicine. 
Obratite se svom liječniku ili ljekarniku za savjet prije nego što uzmete bilo koji lijek.
The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis. 
Rezultati koji su dobiveni u različitim populacijama (primjerice, nestabilna angina ili non-Q infarkt miokarda, niska do visoka razina rizika, šećerna bolest, potreba revaskularizacije, dob, spol itd.) bili su sukladni rezultatima primarne analize.
From literature, limited data in Asian populations are available to assess the clinical implication of genotyping of this CYP on clinical outcome events. 
U literaturi su dostupni ograničeni podaci za procjenu kliničke implikacije genotipizacije ovog CYP enzima na ishode kliničkih događaja u azijatskoj populaciji.
When given to lactating rats, clopidogrel caused a slight delay in the development of the offspring. 
Kad se davao ženkama štakora u vrijeme dojenja, klopidogrel je izazivao neznatno kašnjenje u razvitku mladunčadi.
Patients should be followed carefully for any signs of bleeding including occult bleeding, especially during the first weeks of treatment and/or after invasive cardiac procedures or surgery. 
Bolesnike treba pomno nadzirati radi mogućih znakova krvarenja, uključujući okultno krvarenje, i to poglavito tijekom prvih tjedana liječenja i/ili nakon invazivnih kardioloških postupaka ili kirurških zahvata.
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy. 
U studiji CURE, 823 (6,6%) bolesnika istodobno je primalo antagoniste receptora GPIIb/IIIa.
If you forget to take a dose of Clopidogrel Teva Generics B.V., but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time. 
Ako zaboravite uzeti jednu dozu lijeka Klopidogrel Teva Generics B.V. ali se toga sjetite u roku od 12 sati, odmah uzmite tabletu, a sljedeću tabletu uzmite u uobičajeno vrijeme.
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure. 
Trombotična trombocitopenična purpura (TTP) zabilježena je vrlo rijetko nakon primjene klopidogrela, katkad nakon kratke izloženosti lijeku.
At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and 60%. 
U stanju dinamičke ravnoteže prosječna opažena razina inhibicije, uz dozu od 75 mg na dan, iznosi između 40% i 60%.
After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed. 
Nakon jednokratne i ponovljenih oralnih doza od 75 mg na dan, klopidogrel se brzo apsorbira.
Platelet aggregation and bleeding time gradually returned to baseline values, generally within 5 days after treatment was discontinued. 
Agregacija trombocita i vrijeme krvarenja postupno se vraćaju na početne vrijednosti, obično unutar 5 dana od prekida uzimanja lijeka.
Hallucinations, confusion 
Psihijatrijski poremećaji halucinacije, konfuznost
Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed no genotoxic activity. 
Klopidogrel je testiran u mnogim genotoksičnim studijama in vivo i in vitro i nije pokazao genotoksičnu aktivnost.
By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called thrombosis). 
Sprječavanjem tog nakupljanja, antitrombocitni lijekovi smanjuju mogućnost stvaranja krvnih ugrušaka (proces zvan tromboza).
Marketing Authorisation Holder Teva Generics B.V., Computerweg 10, 3542 DR Utrecht, The Netherlands 
Nositelj odobrenja za stavljanje gotovog lijeka u promet Teva Generics B.V., Computerweg 10, 3542 DR Utrecht, Nizozemska
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER (28x1 film-coated tablets-calendar pack) 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP (BLISTER 28x1 filmom obloženih tableta-kalendarsko pakiranje)
The population included 27.8% women, 58.4% patients ≥60 years (26% ≥70 years) and 54.5% patients who received fibrinolytics. 
Populacija bolesnika uključivala je 27,8% žena, 58,4% bolesnika ≥60 godina (26% ≥70 godina) i 54,5% bolesnika koji su primali fibrinolitike.
There was no observed effect on the rate of rehospitalisation for unstable angina. 
Nije primijećen učinak na ponovljenu hospitalizaciju zbog nestabilne angine.
Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively). 
Klopidogrel i glavni cirkulirajući (neaktivni) metabolit reverzibilno se in vitro vežu za proteine u ljudskoj plazmi (98% odnosno 94%).
Clopidogrel prolongs bleeding time and should be used with caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal and intraocular). 
Klopidogrel produljuje vrijeme krvarenja i mora se davati s oprezom bolesnicima koji imaju lezije s mogućnošću krvarenja (osobito gastrointestinalne i intraokularne).
Clopidogrel was found to have no effect on the fertility of male and female rats and was not teratogenic in either rats or rabbits. 
Klopidogrel nije imao štetnih učinaka na fertilitet muških i ženskih štakora i nije pokazao teratogene učinke na štakorima i kunićima.
The binding is non-saturable in vitro over a wide concentration range. 
Vezanje nije zasićeno in vitro u širokom rasponu koncentracija.
• Active pathological bleeding such as peptic ulcer or intracranial haemorrhage. 
Aktivno patološko krvarenje, poput peptičkog ulkusa ili intrakranijalnog krvarenja.
The MAH must ensure that the system of pharmacovigilance, as described in version version 8 dated November 2009 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market. 
Nositelj odobrenja mora osigurati da je farmakovigilancijski sustav, prikazan u Modulu 1.8.1. nositelja odobrenja, ustrojen i funkcionalan prije i za vrijeme dok je lijek na tržištu.
Manufacturer 
Proizvođači
Some other medicines may influence the use of Clopidogrel Teva Generics B.V. or vice versa. 
Neki lijekovi mogu utjecati na djelovanje Klopidogrel Teva Generics B.V. i obratno.
Recent myocardial infarction (MI), recent stroke or established peripheral arterial disease 
Nedavni infarkt miokarda (IM), nedavni moždani udar ili utvrđena bolest perifernih arterija
The co-primary endpoints were death from any cause and the first occurrence of re-infarction, stroke or death. 
Uz koprimarni ishod bila je povezana smrt iz bilo kojeg uzroka i prvi ponovljeni infarkt, moždani udar ili smrt.
If you cut or injure yourself, it may take slightly longer than usual for bleeding to stop. 
Ako se porežete ili ozlijedite, može trajati dulje nego obično da krvarenje prestane.
Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC code: B01AC-04. 
5.1 Farmakodinamička svojstva Farmakoterapijska skupina: inhibitori agregacije trombocita izuzev heparina, ATK oznaka: B01AC04.
The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1). 
Korist kombinacije klopidogrela s ASK u trajanju dužem od 4 tjedna nije ispitivana u ovom stanju (vidjeti dio 5.1.).
Specific pharmacokinetic studies performed with radiolabelled clopidogrel have shown that the parent compound or its metabolites are excreted in the milk. 
Specifične farmakokinetičke studije provođene s radioaktivno označenim klopidogrelom pokazale su da se izvorna tvar ili njezini metaboliti izlučuju u mlijeko.
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%. 
U studiji CAPRIE, u bolesnika koji su liječeni klopidogrelom ili ASK, ukupna incidencija bilo kakvog krvarenja iznosila je 9,3%.
Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8). 
Zbog opasnosti od krvarenja i hematoloških nuspojava, potrebno je odmah provjeriti krvnu sliku i/ili druge relevantne nalaze kad god se tijekom liječenja pojave klinički znakovi koji ukazuju na krvarenje (vidjeti dio 4.8.).
Moreover, the safety profile of clopidogrel in this subgroup of patients did not raise any particular concern. 
Osim toga, sigurnosni profil klopidogrela nije u toj podskupini bolesnika izazvao bilo kakvu zabrinutost.
Apart from the specific medicinal product interaction information described above, interaction studies with clopidogrel and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed. 
Osim prethodno opisanih interakcija sa specifičnim lijekovima, nisu provedena ispitivanja interakcija klopidogrela s nekim lijekovima koji se obično propisuju bolesnicima s aterotrombotskom bolesti.
Clopidogrel has been evaluated for safety in more than 42,000 patients who have participated in clinical studies, including over 9,000 patients treated for 1 year or more. 
Sigurnost primjene klopidogrela ispitana je na više od 44 000 bolesnika koji su sudjelovali u kliničkim ispitivanjima, uključujući više od 12 000 bolesnika koji su lijek primali godinu ili više dana.
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of clopidogrel. 
Nema dokaza da drugi lijekovi koji smanjuju lučenje želučane kiseline, poput H2 blokatora (osim cimetidina koji je inhibitor CYP2C19) ili antacida, utječu na antitrombocitnu aktivnost klopidogrela.
Magyarország Teva Magyarország Zrt Tel.: +36 1 288 64 00 
Magyarország Teva Gyógyszergyár Zrt Tel.: +36 1 288 64 00
Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months (see section 5.1). 
Rezultati kliničkih ispitivanja podupiru trajanje liječenja do 12 mjeseci, a najveći učinak zabilježen je u trećem mjesecu liječenja (vidjeti dio 5.1.).
No effect on hepatic metabolising enzymes was observed in humans receiving clopidogrel at the therapeutic dose. 
Učinak na jetrene metaboličke enzime nije primijećen u ljudi koji su primali terapijske doze klopidogrela.
A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions. 
Ostali lijekovi: Provedene su određene kliničke studije s klopidogrelom i nekim drugim istodobno primjenjivanim lijekovima kako bi se ispitala mogućnost farmakodinamičkih i farmakokinetičkih interakcija.
What Clopidogrel Teva Generics B.V. looks like and contents of the pack The film-coated tablets are pink, round and slightly convex. 
Kako Klopidogrel Teva Generics B.V. izgleda i sadržaj pakiranja Filmom obložene tablete su ružičaste, okrugle i blago ispupčene.
België/Belgique/Belgien 
Luxembourg/Luxemburg
Platelets are very small structures in the blood, which clump together during blood clotting. 
Trombociti su vrlo mala krvna tjelešca, tzv. krvne pločice, koje se nakupljaju tijekom zgrušavanja krvi.
If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of clopidogrel. 
Ako je potrebno hitno korigirati produljeno vrijeme krvarenja, transfuzija trombocita može smanjiti učinak klopidogrela.
If you become pregnant while taking Clopidogrel Teva Generics B.V., consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
Ako zatrudnite za vrijeme uzimanja lijeka Klopidogrel Teva Generics B.V., odmah se posavjetujte s liječnikom jer nije preporučeno uzimati klopidogrel za vrijeme trudnoće.
In vitro, this metabolic pathway is mediated by CYP3A4, CYP2C19, CYP1A2 and CYP2B6. 
Ovaj metabolički put u in vitro uvjetima posredovan je enzimima CYP3A4, CYP2C19, CYP1A2, i CYP2B6.
Repeated doses of 75 mg per day produced substantial inhibition of ADP-induced platelet aggregation from the first day; this increased progressively and reached steady state between Day 3 and Day 7. 
Ponovljene doze klopidogrela od 75 mg na dan uzrokuju snažnu inhibiciju ADP-om posredovane agregacije trombocita od prvoga dana; to se progresivno pojačava i dostiže stanje dinamičke ravnoteže između dana 3 i dana 7.
Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleed, blood in the urine. 
Krvarenje se može pojaviti u obliku krvarenja u želucu ili crijevima, modrica, hematoma (neuobičajeno krvarenje ili modrica ispod kože), krvarenja iz nosa, krvi u mokraći.
There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day). 
Nije bilo dokaza o karcinogenim učincima kad se klopidogrel davao miševima 78 tjedana i štakorima 104 tjedna u dozama do 77 mg/kg na dan (što predstavlja barem 25 puta veću izloženost nego u ljudi koji primaju kliničku dozu od 75 mg/dan).
NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss. 
Nesteroidni protuupalni lijekovi (NSAIL): u jednoj kliničkoj studiji provedenoj na zdravim dobrovoljcima, istodobna primjena klopidrogela i naproksena povećala je gubitak krvi okultnim krvarenjem iz probavnog trakta.
No antidote to the pharmacological activity of clopidogrel has been found. 
Nije pronađen antidot za farmakološku aktivnost klopidogrela.
For the 28x1 tablets pack size, you can check the day on which you last took the tablet by referring to the calendar printed on the blister. 
Na pakiranju od 28x1 tableta možete pomoću kalendara otisnutog na blisteru provjeriti dan kada ste zadnji put uzeli tabletu Klopidogrel Teva Generics B.V.
Thrombotic Thrombocytopenic Purpura (TTP) 
Trombotična trombocitopenična purpura (TTP)
WHAT CLOPIDOGREL TEVA GENERICS B.V. IS AND WHAT IT IS USED FOR 
Što je Klopidogrel Teva Generics B.V. i za što se koristi
You should take Clopidogrel Teva Generics B.V. for as long as your doctor continues to prescribe it. 
Klopidogrel Teva Generics B.V. trebate uzimati sve dok Vam ga liječnik propisuje.
For patients who did not undergo angiography, the primary endpoint was death or recurrent myocardial infarction by Day 8 or by hospital discharge. 
Za bolesnike kojima nije učinjena angiografija primarni ishod bio je smrt ili ponovljeni infarkt miokarda do osmog dana liječenja ili do otpusta iz bolnice.
Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic or subject to inhibition by other drugs, not all patients will have adequate platelet inhibition. 
Budući da se aktivni metabolit klopidogrela stvara pomoću enzima CYP450, od kojih su neki polimorfni ili podložni inhibiciji drugim lijekovima, svi bolesnici neće imati adekvatnu inhibiciju trombocita.
Clopidogrel significantly reduced the relative risk of death from any cause by 7% (p=0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p=0.002), representing an absolute reduction of 0.5% and 0.9%, respectively. 
Klopidogrel je značajno smanjio relativni rizik od smrti bilo kojeg uzroka za 7% (p=0,029) i relativni rizik kombinacije ponovljenog infarkta, moždanog udara ili smrti za 9% (p=0,002), što je značilo ukupno smanjenje rizika od 0,5% odnosno 0,9%.
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure. 
S obzirom na to da nema dovoljno podataka o primjeni klopidogrela u trudnica, preporučljivo je, kao mjera opreza, ne koristiti klopidogrel za vrijeme trudnoće.
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel Teva Generics B.V.. 
Kao mjera opreza, treba prestati s dojenjem za vrijeme liječenja lijekom Klopidogrel Teva Generics B.V.
Read all of this leaflet carefully before you start taking this medicine. 
Pažljivo pročitajte cijelu uputu prije nego što počnete uzimati ovaj lijek jer sadrži Vama važne podatke.
Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction in terms of major cardiovascular events have been reported from both observational and clinical studies. 
Podaci prijavljeni iz opservacijskih i iz kliničkih studija o kliničkim implikacijama ove farmakokinetičke (PK)/farmakodinamičke (PD) interakcije u smislu značajnih kardiovaskularnih događaja nisu konzistentni.
Each film-coated tablet contains 13 mg hydrogenated castor oil. 
Jedna filmom obložena tableta sadrži 13 mg hidrogeniranog ricinusovog ulja.
However, concomitant administration of 500 mg of ASA twice a day for one day did not significantly increase the prolongation of bleeding time induced by clopidogrel intake. 
Međutim, istodobna primjena 500 mg ASK dva puta na dan tijekom jednog dana nije značajno produljila vrijeme krvarenja već produljeno uzimanjem klopidogrela.
In the myocardial infarction subgroup, most of the patients received ASA for the first few days following the acute myocardial infarction. 
U podskupini s infarktom miokarda većina je bolesnika prvih nekoliko dana nakon akutnog infarkta miokarda primala ASK.
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 ‘Possible side effects') 
Ako ste ipak zabrinuti zbog krvarenja, odmah obavijestite svog liječnika (vidjeti dio 4. "Moguće nuspojave").
In addition to clinical studies experience, adverse reactions have been spontaneously reported. 
Uz iskustvo iz kliničkih ispitivanja, nuspojave su prijavljivane i spontano.
It is characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal dysfunction or fever. 
Karakteriziraju je trombocitopenija i mikroangiopatska hemolitička anemija kojoj mogu biti pridruženi neurološki ispadi, disfunkcija bubrega ili vrućica.
The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism differs according to race/ethnicity (see Pharmacogenetics). 
Prevalencija CYP2C19 alela koji rezultiraju umjerenim i slabim CYP2C19 metabolizmom razlikuje se prema rasi/etničkoj skupini (vidjeti dio "Farmakogenetika").